Phase 1 · Durham, NC
Phase 1 clinical trials in Durham, NC
31 recruiting studies have a site in Durham.
31 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
University of North Carolina, Chapel Hill
- Location
- Durham, NC + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingPhase 1Overnight stay mentioned
A Study of GNTI-122 in Adults Recently Diagnosed With T1D
GentiBio, Inc
- Location
- Durham, NC + 8 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
pH1N1 Blinded Challenge Study
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Durham, NC + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.
David D'Alessio, M.D.
- Location
- Durham, NC
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 1
Macrophage Regulation of Ozone-Induced Lung Inflammation
Robert Tighe, MD
- Location
- Durham, NC
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking
Duke University
- Location
- Durham, NC
- Eligibility basics
- Ages 18–21
- RecruitingPhase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Encoded Therapeutics
- Location
- Durham, NC + 9 other US sites
- Eligibility basics
- Ages 6 mo–17
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Durham, NC + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 1/Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AskBio Inc
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Disc Medicine, Inc
- Location
- Durham, NC + 10 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc.
- Location
- Durham, NC + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Study of GS-0415 and How It Works in People With HIV
Gilead Sciences
- Location
- Durham, NC + 14 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1/Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Tr1X, Inc.
- Location
- Durham, NC + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
UCB Biopharma SRL
- Location
- Durham, NC + 5 other US sites
- Eligibility basics
- Ages 18+ · Women only
- RecruitingPhase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
CRISPR Therapeutics AG
- Location
- Durham, NC + 7 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
Sarepta Therapeutics, Inc.
- Location
- Durham, NC + 10 other US sites
- Eligibility basics
- Ages 2+ · Men only
- RecruitingPhase 1/Phase 2
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
COUR Pharmaceutical Development Company, Inc.
- Location
- Durham, NC + 44 other US sites
- Eligibility basics
- Ages 12–35
- RecruitingPhase 1
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Allogene Therapeutics
- Location
- Durham, NC + 15 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 1/Phase 2
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
CytoAgents, Inc.
- Location
- Durham, NC + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
Denali Therapeutics Inc.
- Location
- Durham, NC + 3 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Location
- Durham, NC + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
- Location
- Durham, NC + 1 other US site
- Eligibility basics
- Ages 18–65
Who these studies look for
Phase 1 studies often have narrow eligibility: specific age and weight ranges, no recent participation in another study, no nicotine, and limits on medications. Some Phase 1 studies recruit patients rather than healthy volunteers, so check each listing.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.